^
    1m
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, National Cancer Institute (NCI) | N=240 --> 2 | Trial completion date: Oct 2027 --> Jun 2027 | Trial primary completion date: Oct 2027 --> Jan 2026
    Enrollment change • Trial completion date • Trial primary completion date • MSI-H • dMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    1m
    Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov)
    P3, N=236, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Mar 2026
    Trial completion • Trial completion date
    |
    AFP (Alpha-fetoprotein)
    |
    AFP elevation
    |
    cisplatin • doxorubicin hydrochloride • irinotecan • temsirolimus • vincristine • fluorouracil topical • dexrazoxane
    1m
    Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Mayo Clinic | Trial completion date: Apr 2030 --> Jun 2029 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date
    |
    Opdivo (nivolumab) • oxaliplatin • leucovorin calcium • Proleukin (aldesleukin) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    1m
    GIANT: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (clinicaltrials.gov)
    P2, N=176, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    gemcitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical
    2ms
    Comparing the Safety and Efficacy of CO2 LADD TAC With and Without 5-FU for Hypertrophic Burn Scars: A Triple-Blinded, Split Scar RCT (clinicaltrials.gov)
    P=N/A, N=65, Not yet recruiting, University of California, Davis
    New trial
    |
    fluorouracil topical
    2ms
    Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2029 --> Mar 2031 | Trial primary completion date: Dec 2029 --> Mar 2028 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • oxaliplatin • irinotecan • leucovorin calcium • Visudyne (verteporfin) • fluorouracil topical
    2ms
    AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer (clinicaltrials.gov)
    P1, N=46, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P1 trial
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • oxaliplatin • irinotecan • Yutuo (zimberelimab) • leucovorin calcium • fluorouracil topical
    2ms
    Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    capecitabine • fluorouracil topical
    3ms
    A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, National Cancer Institute (NCI) | N=95 --> 11 | Trial completion date: Jun 2026 --> May 2027 | Trial primary completion date: Jun 2026 --> Feb 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • fluorouracil topical • Jelmyto (mitomycin urothelial gel)
    3ms
    S1513: FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=123, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    irinotecan • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical
    3ms
    A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers (clinicaltrials.gov)
    P1, N=25, Completed, Massachusetts General Hospital | Trial completion date: Feb 2024 --> Apr 2026
    Trial completion date
    |
    carboplatin • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    3ms
    New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study (clinicaltrials.gov)
    P2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=105 --> 0 | Trial completion date: Apr 2027 --> Apr 2026 | Active, not recruiting --> Withdrawn | Trial primary completion date: Apr 2027 --> Apr 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical